Article (Scientific journals)
Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg serovconversion is associated with high relapse rates and fatal outcomes
Van Hees, S; Bourgeois, S; Van Vlierberghe, H et al.
2018In Alimentary Pharmacology and Therapeutics, 47 (8), p. 1170-1180
Peer Reviewed verified by ORBi
 

Files


Full Text
Hees_et_al-2018-Alimentary_Pharmacology_&_Therapeutics.pdf
Publisher postprint (496.05 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
Gastroenterology & hepatology
Author, co-author :
Van Hees, S
Bourgeois, S
Van Vlierberghe, H
Sersté, T
Francque, S
Michielsen, P
Sprengers, D
Reynaert, H
Henrion, J
Negrin Dastis, S
DELWAIDE, Jean ;  Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Lasser, L
Decaestecker, J
Orlent, H
Janssens, F
Robaeys, G
Colle, I
Starkel, P
Moreno, C
Nevens, F
Vanwolleghem, T
More authors (11 more) Less
Language :
English
Title :
Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg serovconversion is associated with high relapse rates and fatal outcomes
Publication date :
March 2018
Journal title :
Alimentary Pharmacology and Therapeutics
ISSN :
0269-2813
eISSN :
1365-2036
Publisher :
Blackwell, Oxford, United Kingdom
Volume :
47
Issue :
8
Pages :
1170-1180
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 03 March 2018

Statistics


Number of views
59 (6 by ULiège)
Number of downloads
20 (4 by ULiège)

Scopus citations®
 
45
Scopus citations®
without self-citations
38
OpenCitations
 
41

Bibliography


Similar publications



Contact ORBi